Pancreatic Cancer Conference, London 2026 – Cancer Research UK

Pancreatic Cancer Conference, London 2026 – Cancer Research UK

Registration is now open for the Pancreatic Cancer Conference organised by Cancer Research UK. The event will take place in London from 7–9 July.

https://www.cancerresearchuk.org/for-researchers/how-we-deliver-research/scientific-events-and-webinars/pancreatic-cancer-conference

This conference will bring together an international, multidisciplinary community to present the latest scientific advances, foster meaningful debate, and enable new collaborations to drive progress in pancreatic cancer research.

The programme will feature speakers from around the world in scientific sessions and panel discussions, with presentations spanning basic, translational and clinical research. Topics will range from examining the biology of the exposome and its role in tumour initiation and progression to exploring the systemic physiological disruptions associated with advanced-stage disease.

This is a must-attend event for those working in pancreatic cancer research or related disciplines and is open to researchers at all career stages worldwide. The conference will include poster sessions and extensive networking opportunities, particularly for early career researchers.

At ALIPANC, we encourage you to take part — don’t miss it!

Early bird registration: until 9 January
Abstract submission deadline: 15 March

ALPANC researchers publish study protocol comparing 3D modeling versus conventional CT

3D-PANC study protocol: Is three-dimensional imaging technology superior to computed tomography for assessing the response to neoadjuvant treatment in patients with borderline or locally advanced pancreatic adenocarcinoma?

This study focuses on improving the preoperative assessment of borderline or locally advanced pancreatic adenocarcinoma (PAC) after neoadjuvant chemotherapy, as conventional computed tomography (CT) has been shown to have very low accuracy in determining which patients will benefit from surgical resection. The hypothesis proposes that applying 3D-MSP (Model for Surgery Planning) technology to CT images will significantly increase accuracy in identifying resectable patients.

The primary objective of the study is to compare the accuracy of 3D-MSP with standard CT, focusing on the diagnosis of post-chemotherapy vascular involvement (venous and/or arterial). To achieve this, a prospective multicenter study is planned that will include, over a one-year period, all patients with PAC undergoing neoadjuvant therapy followed by surgical exploration. The diagnostic accuracy of both techniques (3D-MSP and CT) will be evaluated by comparing their results with intraoperative findings and final histopathological analysis.

Additionally, the study aims to analyze the accuracy of 3D-MSP in demonstrating response to chemotherapy, assess the impact of radiomics (quantitative texture analysis), and validate the usefulness of this three-dimensional technology for education, patient communication, and detailed surgical planning.

Marina Garcés Albir, Francisco García García, Isabel Mora Oliver, Elena Muñoz Forner, Luis Sabater Orti, Dimitri Dorcaratto; GRUPO 3D-PANC Integrantes Grupo 3D-PANC

Department of General and Digestive Surgery, Hospital Clínico Universitario de Valencia, Valencia, Spain; Department of General and Digestive Surgery, School of Medicine, University of Valencia, Valencia, Spain; INCLIVA: Biomedical Research Institute, Valencia, Spain.

Read the full article here!

More about the group here.
New potential therapeutic target for pancreatic cancer identified by ALIPANC researchers

New potential therapeutic target for pancreatic cancer identified by ALIPANC researchers

The study by Parejo-Alonso et al. identifies PPAR-δ as a critical transcription factor mediating pancreatic cancer cell adaptation to microenvironmental stress.

Normally involved in lipid metabolism, PPAR-δ is overexpressed in pancreatic tumors and, under metabolic stress, senses lipidomic alterations, triggering metabolic reprogramming that enhances glycolysis and promotes a pro-invasive phenotype.

In vitro and in vivo models confirm that pharmacological inhibition of PPAR-δ reverses these adaptations and reduces metastatic potential, highlighting its relevance as a promising therapeutic target for pancreatic cancer treatment.

Complete information at the following link: https://pubmed.ncbi.nlm.nih.gov/40607925/

ALIPANC researchers develop a new therapeutic combination in preclinical models of pancreatic cancer.

This study conducted by researchers from Vigo presents an innovative sequential therapeutic strategy against pancreatic ductal adenocarcinoma, one of the most lethal cancers due to its stromal barrier that prevents drug penetration.

The novelty lies in the biphasic and sequential treatment: first, lipid nanoparticles containing siRNA that silence the transcription factors YAP1 and FOSL1 are administered, weakening the tumor’s protective stroma; then combination chemotherapy (entinostat and gemcitabine) is applied, which penetrates more effectively into the now permeable tumor tissue.

Results in preclinical models (mouse xenografts and patient organoids) demonstrated reduced fibrotic tissue, increased drug penetration and superior therapeutic efficacy. This approach represents a paradigm shift from traditional combination therapies.

 

Immacolata Maietta, Patricia Domínguez Arístegui, Iban González Álvarez, Omayra Rodríguez Atanes, Eva María García Fontán, Susana Teijeira Bautista, África González-Fernández, Rosana Simón-Vázquez, Sequential YAP1/FOSL1 silencing and epigenetic therapy to overcome stromal barriers in pancreatic cancer, International Journal of Pharmaceutics, 2025, vol. 684, 126155. https://doi.org/10.1016/j.ijpharm.2025.126155.

Access the full article at the following link: https://pdf.sciencedirectassets.com/271189/1-s2.0-S0378517325X00156/1-s2.0-S0378517325009925/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEKX%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJHMEUCIEmy%2FlDACu%2BJwqxPbPi%2B%2FdT8L3F3qWlzvnC2iVZ8xzfLAiEAiQlAXbjBadOgjBg8Wl%2BrHpj2eQpEWLzo4KCl6C6r4eAqswUIbhAFGgwwNTkwMDM1NDY4NjUiDN1865%2B9jlmTrQV6mSqQBaBj4CJJhNs7rR9%2FaKngxlEdVyp3ciVQDZ86XZQRWnw%2FonwJX3RAqszW3YWaaFbzNVdRDwsWyEqwvnldCO3fKo%2BZZmH%2Fw4zIkdGCq2OSY31%2Bv3lpio2zYlE6Rq8su75k1ZreitM81AmUfjbJB%2FCNwFoFaREMHgtGqWJKCx0%2FeTc8pofkmPmmpbm%2BF%2Bu3JdrtXZ5Zt885mqylBP0zXDovPhguqx%2BpQT8hzMhSRU20mx7Z5P6UM0VpCKx%2BGYHXqN6%2BbEyiybTi1Q2iFPG7t%2BUjpOZEKZZLdezVm%2BC9O2Q0FVzgsC63ffGKPCLS%2BH2hUdfSxzSWq9ij14MiH2h1jlsjGdw4xUDuL4uXesK5ezbyy6JT6%2FH46QdNZvitErBc5d8cfkNHhL0I%2F0GARzLYyOkjhFlZBCjKiH83gkLH0wEjSo2k5aHOLr4Ts49WrF9k8vL5fXEGO7fSSjPCnaV8DB43SO0l6vPHX%2BydavJF59AvMtuijHUxs6wmgzBulOsphtep2V5NDexVilR9IhpJtHOMR15876hFAF%2By3W7W%2FhjuHsnRaTQ3Rw7VHMQB%2BNGzd9JdZ5BQKjh%